Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials
- 4 May 2016
- journal article
- Published by Elsevier BV in Ophthalmology
- Vol. 123 (7), 1521-1529
- https://doi.org/10.1016/j.ophtha.2016.03.037
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Pigment Epithelial Detachment Followed by Retinal Cystoid Degeneration Leads to Vision Loss in Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2015
- Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategyBritish Journal of Ophthalmology, 2014
- Intravitreal Aflibercept Injection for Neovascular Age-related Macular DegenerationOphthalmology, 2013
- Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- QUANTITATIVE CHANGES IN RETINAL PIGMENT EPITHELIAL DETACHMENTS AS A PREDICTOR FOR RETREATMENT WITH ANTI-VEGF THERAPYRetina, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?Retina, 2010
- Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centresBritish Journal of Ophthalmology, 2010
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006